Regeneron Pharmaceuticals' Upcoming Melanoma Data Likely to Look Competitive, RBC Says

MT Newswires Live12-10 00:28

Regeneron Pharmaceuticals' (REGN) upcoming LAG-3 melanoma readout will likely look competitive, RBC Capital Markets said in a note Tuesday.

The investment firm said Regeneron market expectations for Regeneron's "peak sales numbers do have room to move up."

However, based on RBC's analysis and other feedback, it is not certain that the differentiation versus

Bristol-Myers Squibb's (BMY) Opdualag will be "indisputable enough to drive another major leg of major stock upside from here," the note said.

The investment firm said the first phase 3 results from the LAG-3 fianlimab plus cemiplimab combo versus pembro to treat 1L metastatic melanoma are expected in H1 2026.

RBC has a sector perform rating on Regeneron and $708 price target.

Price: 699.73, Change: -3.53, Percent Change: -0.50

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment